메뉴 건너뛰기




Volumn 14, Issue 1, 2000, Pages 31-41

Comparison of the efficacy and safety of losartan (50-100 mg) with the T-type calcium channel blocker mibefradil (50-100 mg) in mild to moderate hypertension

Author keywords

Clinical trial; Efficacy; Hypertension; Losartan; Mibefradil; Safety

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; LOSARTAN; MIBEFRADIL;

EID: 0033954240     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2000.tb00391.x     Document Type: Article
Times cited : (6)

References (46)
  • 1
    • 0031603035 scopus 로고    scopus 로고
    • Use of calcium channel blockers in hypertension
    • [1] Conlin P.R., Williams G.H., Use of calcium channel blockers in hypertension, Adv. Intern. Med. 43 (1998) 533 562.
    • (1998) Adv. Intern. Med. , vol.43 , pp. 533
    • Conlin, P.R.1    Williams, G.H.2
  • 2
    • 2642642140 scopus 로고    scopus 로고
    • Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade
    • [2] Noll G., Luscher T.F., Comparative pharmacological properties among calcium channel blockers: T-channel versus L-channel blockade, Cardiology Suppl. 1 89 (1998) 10-15.
    • (1998) Cardiology Suppl. , vol.89 , Issue.SUPPL. 1 , pp. 10-15
    • Noll, G.1    Luscher, T.F.2
  • 3
    • 0030892635 scopus 로고    scopus 로고
    • Pharmacological aspects of calcium channel blockers
    • [3] Scholz H., Pharmacological aspects of calcium channel blockers, Cardiovasc. Drugs Ther. Suppl. 3 10 (1997) 869 872.
    • (1997) Cardiovasc. Drugs Ther. Suppl. , vol.3-10 , pp. 869
    • Scholz, H.1
  • 4
    • 0031466388 scopus 로고    scopus 로고
    • Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker
    • [4] Clozel J.P., Ertel E.A., Ertel S.I., Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker, J. Hypertens. Suppl. 15 (5) (1997) S17-S25.
    • (1997) J. Hypertens. Suppl. , vol.15 , Issue.5
    • Clozel, J.P.1    Ertel, E.A.2    Ertel, S.I.3
  • 5
    • 0030574227 scopus 로고    scopus 로고
    • Pharmacologic and therapeutic differences among calcium channel antagonists: Profile of mibefradil, a new calcium antagonist
    • [5] Triggle D.J., Pharmacologic and therapeutic differences among calcium channel antagonists: profile of mibefradil, a new calcium antagonist, Am. J. Cardiol. 78 (9A) (1996) 7-12.
    • (1996) Am. J. Cardiol. , vol.78 , Issue.9 A , pp. 7-12
    • Triggle, D.J.1
  • 7
    • 0031971534 scopus 로고    scopus 로고
    • Mibefradil, a pharmacologically distinct calcium antagonist
    • [7] Ernst M.E., Kelly M.W., Mibefradil, a pharmacologically distinct calcium antagonist, Pharmacotherapy 18 (3) (1998) 463 485.
    • (1998) Pharmacotherapy , vol.18 , Issue.3 , pp. 463
    • Ernst, M.E.1    Kelly, M.W.2
  • 8
    • 0029609806 scopus 로고
    • Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist
    • [8] Petrie J.R., Glen S.K., MacMahon M., Crome R., Meredith P.A., Elliott H.L., Reid J.L., Haemodynamics, cardiac conduction and pharmacokinetics of mibefradil (Ro 40-5967), a novel calcium antagonist, J. Hypertens. 13 (12 Pt 2) (1995) 1842-1846.
    • (1995) J. Hypertens. , vol.13 , Issue.12 PT 2 , pp. 1842-1846
    • Petrie, J.R.1    Glen, S.K.2    MacMahon, M.3    Crome, R.4    Meredith, P.A.5    Elliott, H.L.6    Reid, J.L.7
  • 9
    • 0030063405 scopus 로고    scopus 로고
    • Nonlinear pharmacokinetics of mibefradil in the dog
    • [9] Skerjanec A., Tawfik S., Tam Y.K., Nonlinear pharmacokinetics of mibefradil in the dog, J. Pharm. Sci. 85 (2) (1996) 189-192.
    • (1996) J. Pharm. Sci. , vol.85 , Issue.2 , pp. 189-192
    • Skerjanec, A.1    Tawfik, S.2    Tam, Y.K.3
  • 10
    • 0030694359 scopus 로고    scopus 로고
    • Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris
    • [10] Brogden R.N., Markham A., Mibefradil. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of hypertension and angina pectoris, Drugs 54 (5) (1997) 774-793.
    • (1997) Drugs , vol.54 , Issue.5 , pp. 774-793
    • Brogden, R.N.1    Markham, A.2
  • 11
    • 0029885746 scopus 로고    scopus 로고
    • Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): A new generation of calcium antagonists? Mibefradil International Study Group
    • [11] Bernink P.J., Prager G., Schelling A., Kobrin I., Antihypertensive properties of the novel calcium antagonist mibefradil (Ro 40-5967): a new generation of calcium antagonists? Mibefradil International Study Group, Hypertension 27 (3 Pt 1) (1996) 426-432.
    • (1996) Hypertension , vol.27 , Issue.3 PT 1 , pp. 426-432
    • Bernink, P.J.1    Prager, G.2    Schelling, A.3    Kobrin, I.4
  • 12
    • 0031437326 scopus 로고    scopus 로고
    • Cardiovascular care with the new T-type calcium channel antagonist: Possible role of attendant sympathetic nervous system inhibition
    • [12] Buhler F.R., Cardiovascular care with the new T-type calcium channel antagonist: possible role of attendant sympathetic nervous system inhibition, J. Hypertens. Suppl. 15 (5) (1997) S3-S7.
    • (1997) J. Hypertens. Suppl. , vol.15 , Issue.5
    • Buhler, F.R.1
  • 13
    • 0027967663 scopus 로고
    • The Ca( + + )-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca + + channels
    • [13] Mehrke G., Zong X.G., Flockerzi V., Hofmann F., The Ca( + + )-channel blocker Ro 40-5967 blocks differently T-type and L-type Ca + + channels, J. Pharmacol. Exp. Ther. 271 (3) (1994) 1483-1488.
    • (1994) J. Pharmacol. Exp. Ther. , vol.271 , Issue.3 , pp. 1483-1488
    • Mehrke, G.1    Zong, X.G.2    Flockerzi, V.3    Hofmann, F.4
  • 14
    • 0030861535 scopus 로고    scopus 로고
    • Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension
    • [14] Oparil S., Bernink P., Bursztyn M., Carney S., Kobrin I., Antihypertensive effects of mibefradil in the treatment of mild-to-moderate systemic hypertension, Am. J. Cardiol. 80 (4B) (1997) 12C 19C.
    • (1997) Am. J. Cardiol. , vol.80 , Issue.4 B
    • Oparil, S.1    Bernink, P.2    Bursztyn, M.3    Carney, S.4    Kobrin, I.5
  • 15
    • 0032496879 scopus 로고    scopus 로고
    • Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers
    • [15] Mullins M.E., Horowitz B.Z., Linden D.H., Smith G.W., Norton R.L., Stump J., Life-threatening interaction of mibefradil and beta-blockers with dihydropyridine calcium channel blockers, JAMA (J. Am. Med. Assoc.) 280 (2) (1998) 157-158.
    • (1998) JAMA (J. Am. Med. Assoc.) , vol.280 , Issue.2 , pp. 157-158
    • Mullins, M.E.1    Horowitz, B.Z.2    Linden, D.H.3    Smith, G.W.4    Norton, R.L.5    Stump, J.6
  • 16
    • 1542640490 scopus 로고    scopus 로고
    • Rhabdomyolysis due to interaction of simvastatin with mibefradil
    • [16] Schmassmann-Suhijar D., Bullingham R., Gasser R., Schmutz J., Haefeli W.E., Rhabdomyolysis due to interaction of simvastatin with mibefradil [letter]. Lancet 351 (9120) (1998) 1929 1930.
    • (1998) Lancet , vol.351 , Issue.9120 , pp. 1929
    • Schmassmann-Suhijar, D.1    Bullingham, R.2    Gasser, R.3    Schmutz, J.4    Haefeli, W.E.5
  • 17
    • 85077295695 scopus 로고    scopus 로고
    • Announce new drug-interaction warnings for mibefradil [news]
    • [17] Roche, FDA announce new drug-interaction warnings for mibefradil [news]. Am J. Health Syst. Pharm. 55 (3) (1998) 210.
    • (1998) Am J. Health Syst. Pharm. , vol.55 , Issue.3 , pp. 210
    • Roche, F.D.A.1
  • 18
    • 0032551211 scopus 로고    scopus 로고
    • What lessons can be learnt from withdrawal of mibefradil from the market?
    • [18] Po A.L., Zhang W.Y., What lessons can be learnt from withdrawal of mibefradil from the market?, Lancet 351 (9119) (1998) 1829 1830.
    • (1998) Lancet , vol.351 , Issue.9119 , pp. 1829
    • Po, A.L.1    Zhang, W.Y.2
  • 22
    • 0031768054 scopus 로고    scopus 로고
    • Pharmacology of angiotensin receptors and AT1 receptor blockers
    • [22] Chung O., Unger T., Pharmacology of angiotensin receptors and AT1 receptor blockers, Basic Res. Cardiol. 93 (suppl. 2) (1998) 15-23.
    • (1998) Basic Res. Cardiol. , vol.93 , Issue.SUPPL. 2 , pp. 15-23
    • Chung, O.1    Unger, T.2
  • 23
    • 0008890571 scopus 로고    scopus 로고
    • Physiological and pharmacological implications of AT1 vs. AT2 receptors
    • [23] Chung O., Stoll M., Unger T., Physiological and pharmacological implications of AT1 vs. AT2 receptors, Blood Pressure 5 (1996) 42-47.
    • (1996) Blood Pressure , vol.5 , pp. 42-47
    • Chung, O.1    Stoll, M.2    Unger, T.3
  • 24
    • 0031427248 scopus 로고    scopus 로고
    • Rationale and pharmacology of angiotensin II receptor antagonists: Current status and future issues
    • [24] Johnston C.I., Naitoh M., Burrell L.M., Rationale and pharmacology of angiotensin II receptor antagonists: current status and future issues, J. Hypertens. Suppl. 15 (7) (1997) S3-S6.
    • (1997) J. Hypertens. Suppl. , vol.15 , Issue.7
    • Johnston, C.I.1    Naitoh, M.2    Burrell, L.M.3
  • 25
    • 0029743723 scopus 로고    scopus 로고
    • A new class of antihypertensive therapy: Angiotensin II receptor antagonists
    • [25] Ellis M.L., Patterson J.H., A new class of antihypertensive therapy: angiotensin II receptor antagonists, Pharmacotherapy 16 (5) (1996) 849-860.
    • (1996) Pharmacotherapy , vol.16 , Issue.5 , pp. 849-860
    • Ellis, M.L.1    Patterson, J.H.2
  • 26
    • 0029777512 scopus 로고    scopus 로고
    • An in-patient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension
    • [26] Byyny R.L., Merrill D.D., Bradstreet T.E., Sweet C.S., An in-patient trial of the safety and efficacy of losartan compared with placebo and enalapril in patients with essential hypertension, Cardiovasc. Drugs Ther. 10 (3) (1996) 313-319.
    • (1996) Cardiovasc. Drugs Ther. , vol.10 , Issue.3 , pp. 313-319
    • Byyny, R.L.1    Merrill, D.D.2    Bradstreet, T.E.3    Sweet, C.S.4
  • 27
    • 0028935595 scopus 로고
    • Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
    • [27] Goldberg A.I., Dunlay M.C., Sweet C.S., Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension, Am. J. Cardiol. 75 (12) (1995) 793-795.
    • (1995) Am. J. Cardiol. , vol.75 , Issue.12 , pp. 793-795
    • Goldberg, A.I.1    Dunlay, M.C.2    Sweet, C.S.3
  • 28
    • 0030798211 scopus 로고    scopus 로고
    • Clinical safety and tolerability of losartan
    • [28] Weber M., Clinical safety and tolerability of losartan, Clin. Ther. 19 (4) (1997) 604-616.
    • (1997) Clin. Ther. , vol.19 , Issue.4 , pp. 604-616
    • Weber, M.1
  • 29
    • 0029932496 scopus 로고    scopus 로고
    • Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension
    • [29] Goa K.L., Wagstaff A.J., Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension, Drugs 51 (5) (1996) 820-845.
    • (1996) Drugs , vol.51 , Issue.5 , pp. 820-845
    • Goa, K.L.1    Wagstaff, A.J.2
  • 31
    • 0030338821 scopus 로고    scopus 로고
    • Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist in the treatment of hypertension
    • [31] Mallion J.M., Goldberg A.I., Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist in the treatment of hypertension, Blood Press Suppl. 2 (1996) 82-86.
    • (1996) Blood Press Suppl. , vol.2 , pp. 82-86
    • Mallion, J.M.1    Goldberg, A.I.2
  • 32
    • 9044220224 scopus 로고
    • Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension
    • [32] Tikkanen I., Omvik P., Jensen H.A., Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension, J. Hypertens. 13 (11) (1995) 1343-1351.
    • (1995) J. Hypertens. , vol.13 , Issue.11 , pp. 1343-1351
    • Tikkanen, I.1    Omvik, P.2    Jensen, H.A.3
  • 33
    • 0029058333 scopus 로고
    • Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension
    • [33] Dahlof B., Keller S.E., Makris L., Goldberg A.I., Sweet C.S., Lim N.Y., Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension, Am. J. Hypertens. 8 (6) (1995) 578-583.
    • (1995) Am. J. Hypertens. , vol.8 , Issue.6 , pp. 578-583
    • Dahlof, B.1    Keller, S.E.2    Makris, L.3    Goldberg, A.I.4    Sweet, C.S.5    Lim, N.Y.6
  • 34
    • 0029153169 scopus 로고
    • Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension
    • [34] Chan J.C., Critchley J.A., Lappe J.T., Raskin S.J., Snavely D., Goldberg A.I., Sweet C.S., Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension, J. Hum. Hypertens. 9 (9) (1995) 765-771.
    • (1995) J. Hum. Hypertens. , vol.9 , Issue.9 , pp. 765-771
    • Chan, J.C.1    Critchley, J.A.2    Lappe, J.T.3    Raskin, S.J.4    Snavely, D.5    Goldberg, A.I.6    Sweet, C.S.7
  • 35
    • 0029065095 scopus 로고
    • A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension
    • [35] Gradman A.H., Arcuri K.E., Goldberg A.I., Ikeda L.S., Nelson E.B., Snavely D.B., Sweet C.S., A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension, Hypertension 25 (6) (1995) 1345-1350.
    • (1995) Hypertension , vol.25 , Issue.6 , pp. 1345-1350
    • Gradman, A.H.1    Arcuri, K.E.2    Goldberg, A.I.3    Ikeda, L.S.4    Nelson, E.B.5    Snavely, D.B.6    Sweet, C.S.7
  • 36
    • 0031017243 scopus 로고    scopus 로고
    • Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension
    • [36] Ikeda L.S., Harm S.C., Arcuri K.E., Goldberg A.I., Sweet C.S., Comparative antihypertensive effects of losartan 50 mg and losartan 50 mg titrated to 100 mg in patients with essential hypertension, Blood Press. 6 (1) (1997) 35-43.
    • (1997) Blood Press , vol.6 , Issue.1 , pp. 35-43
    • Ikeda, L.S.1    Harm, S.C.2    Arcuri, K.E.3    Goldberg, A.I.4    Sweet, C.S.5
  • 37
    • 0025215247 scopus 로고
    • Power and sample size calculations. A review and computer program
    • [37] Dupont W.D., Plummer W.D., Power and sample size calculations. A review and computer program, Controlled Clinical Trials 11 (1990) 116-128.
    • (1990) Controlled Clinical Trials , vol.11 , pp. 116-128
    • Dupont, W.D.1    Plummer, W.D.2
  • 38
    • 0031801116 scopus 로고    scopus 로고
    • Mibefradil, a T-channel-selective calcium antagonist: Clinical trials in hypertension
    • [38] Oparil S., Mibefradil, a T-channel-selective calcium antagonist: clinical trials in hypertension, Am. J. Hypertens. 11 (1998) 88S-94S.
    • (1998) Am. J. Hypertens. , vol.11
    • Oparil, S.1
  • 39
    • 0031081764 scopus 로고    scopus 로고
    • The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension
    • [39] Lacourciere Y., Poirier L., Lefebvre J., Archambault F., Dalle Ave S., Ward C., Lindberg E., The antihypertensive efficacy of the novel calcium antagonist mibefradil in comparison with nifedipine GITS in moderate to severe hypertensives with ambulatory hypertension, Am. J. Hypertens. 10 (2) (1997) 189-196.
    • (1997) Am. J. Hypertens. , vol.10 , Issue.2 , pp. 189-196
    • Lacourciere, Y.1    Poirier, L.2    Lefebvre, J.3    Archambault, F.4    Dalle Ave, S.5    Ward, C.6    Lindberg, E.7
  • 40
    • 0030751117 scopus 로고    scopus 로고
    • Losartan, an orally active angiotensin (AT1) receptor antagonist: A review of its efficacy and safety in essential hypertension
    • [40] McIntyre M., Caffe S.E., Michalak R.A., Reid J.L., Losartan, an orally active angiotensin (AT1) receptor antagonist: a review of its efficacy and safety in essential hypertension, Pharmacol. Ther. 74 (2) (1997) 181-194.
    • (1997) Pharmacol. Ther. , vol.74 , Issue.2 , pp. 181-194
    • McIntyre, M.1    Caffe, S.E.2    Michalak, R.A.3    Reid, J.L.4
  • 42
    • 0026559238 scopus 로고
    • American Society of Hypertension: Recommendations for routine blood pressure measurement by indirect cuff sphygmamanometry
    • [42] American Society of Hypertension: Recommendations for routine blood pressure measurement by indirect cuff sphygmamanometry, Am. J. Hypertens. 5 (1992) 207-209.
    • (1992) Am. J. Hypertens. , vol.5 , pp. 207-209
  • 43
    • 0027483749 scopus 로고
    • The guidelines for the management of mild hypertension: Memorandum from a WHO ISH meeting
    • [43] Zanchetti A., Chalmers J.P., Arakawa K., Gyarfas I., Hamet P., Hansson L. et al., The guidelines for the management of mild hypertension: memorandum from a WHO ISH meeting, Blood Press. 2 (2) (1993) 86-100.
    • (1993) Blood Press , vol.2 , Issue.2 , pp. 86-100
    • Zanchetti, A.1    Chalmers, J.P.2    Arakawa, K.3    Gyarfas, I.4    Hamet, P.5    Hansson, L.6
  • 44
    • 0025043248 scopus 로고
    • Blood pressure and coronary heart disease
    • [44] Collins R., Peto R., Godwin J., MacMahon S., Blood pressure and coronary heart disease, Lancet 336 (8711) (1990) 370-371.
    • (1990) Lancet , vol.336 , Issue.8711 , pp. 370-371
    • Collins, R.1    Peto, R.2    Godwin, J.3    MacMahon, S.4
  • 46
    • 0027516115 scopus 로고
    • Influence of heart rate on mortality among persons with hypertension: The Framingham Study
    • [46] Gillman M.W., Kannel W.B., Belanger A., D'Agostino R.B., Influence of heart rate on mortality among persons with hypertension: the Framingham Study, Am. Heart J. 125 (1993) 1148-1154.
    • (1993) Am. Heart J. , vol.125 , pp. 1148-1154
    • Gillman, M.W.1    Kannel, W.B.2    Belanger, A.3    D'Agostino, R.B.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.